- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
In children aged 6 to 11 years, exposure to a one-time dose of 15, 30 or 60 mg fexofenadine is proportional and comparable to a one-time dose of 30, 60 mg or 120 mg respectively in adults. A dose of 30 mg twice daily in children therefore results in a similar AUC and Cmax as in adults on a dose of 120 mg once daily.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Allergic rhinitis and chronic urticaria |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
- GFR ≥50: dose adjustment not needed
- GFR 30-50: 50% of normal reversal dose, adjustment of dosing interval is not necessary.
- GFR 10-30: 50% of normal reversal dose, adjustment of dosing interval is not necessary.
- GFR <10: a general recommendation cannot be given. Weigh up the usage and determine the dosage per patient.
Clinical consequences
With impaired renal function, Cmax and half-life of fexofenadine may increase. This increases the risk of adverse reactions.
Clinical implications:
Prolongation of the QTc interval may occur. Further possible central nervous system side effects.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Piperazine derivatives | ||
|---|---|---|
| R06AE07 | ||
| R06AE03 | ||
| Other antihistamines for systemic use | ||
|---|---|---|
| R06AX13 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- sanofi-aventis Netherlands B.V., SPC Telfast 30 mg (RVG 28085) 4 nov 2013, www.cbg-meb.nl
- Nederlandse Vereniging voor Dermatologie en Venereologie, Richtlijn Chronische spontane urticaria., www.ndvd.nl, 03-12-2015
- Zuberbier T, et al, The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update,, Allergy,, 2014, Jul;69(7), 868-87
- NKFK Workinggroup Acute Kidney Impairment, Extrapolation of KNMP risk analysis "Impaired renal function" for adults to children, 20 Dec 2021
- Opella Healthcare France SAS, SmPC Telfast 180 mg (RVG 21625) 15-07-2023, www.geneesmiddelinformatiebank.nl
- Teva B.V. , SmPC Fexofenadine HCl Teva 120 mg (35246) 06-02-2024, www.geneesmiddelinformatiebank.nl
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
